Results 141 to 150 of about 86,092 (288)

Brain natriuretic peptide and NT-proBNP levels reflect pulmonary artery systolic pressure in trekkers at high altitude. [PDF]

open access: yes, 2013
Our objective was to evaluate the utility of the natriuretic peptides BNP (brain natriuretic peptide) and NT-proBNP as markers of pulmonary artery systolic pressure (PASP) in trekkers ascending to high altitude (HA). 20 participants had BNP and NT-proBNP
Begley, J   +9 more
core  

Cardiac resynchronization therapy and pulmonary artery banding in advanced heart failure infants with left ventricular dilated cardiomyopathy and left bundle branch block

open access: yesPediatric Investigation, EarlyView.
The combination of cardiac resynchronization therapy and pulmonary artery banding was associated with substantial improvement in advanced heart failure infants with left ventricular dilated cardiomyopathy and left bundle branch block. Most patients exhibited marked improvement in clinical status and ventricular function, along with a reduction in QRS ...
Min Zeng   +8 more
wiley   +1 more source

N-terminal pro atrial natriuretic peptide as a prognostic marker of cardiac resynchronization therapy recipients. [PDF]

open access: yesInt J Cardiol Heart Vasc, 2023
Ueda N   +16 more
europepmc   +1 more source

6‐Shogaol Attenuates Doxorubicin‐Induced Cardiac and Skeletal Muscle Atrophy by Inhibiting E3 Ubiquitin Ligases and Necroptosis

open access: yesPhytotherapy Research, EarlyView.
Doxorubicin induces cardiac and skeletal muscle atrophy by upregulating E3 ubiquitin ligases, inhibiting myogenic regulatory factors, and activating necroptosis. Cardiac atrophy can further exacerbate cardiotoxicity. 6‐Shogaol negatively regulates these processes and attenuates doxorubicin‐induced cardiac and skeletal muscle atrophy.
Xipeng Sun   +5 more
wiley   +1 more source

Congestion, decongestion, renal function and diuretics in (ESC) heart failure

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 730-732, April 2025.
Jan Biegus   +2 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

open access: yesBritish Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

New biosensors and transgenic mice for multiplex cGMP imaging

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a versatile second messenger that is important for human (patho‐)physiology and pharmacotherapy. Live‐cell imaging of cGMP with biosensors allows to elucidate its spatiotemporal dynamics in real time under close‐to‐native conditions. However, to monitor two separate cGMP pools or cGMP/cAMP
Markus Wolters   +6 more
wiley   +1 more source

Can't Patch Everything: Personalized Medicine for Cell Therapy in Dilated Cardiomyopathy

open access: yes, 2021
Journal of the American Heart Association, EarlyView.
Andrew Sundin   +2 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy